Immunomedics Announces U.S. Patent for IMMU-114

Immunomedics Announces U.S. Patent for IMMU-114

MORRIS PLAINS, N.J., May 13, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc.,
(Nasdaq:IMMU) today announced the issuance of U.S. patent no. 8,722,047 for
the Company's patent application "Humanized anti-HLA-DR antibodies," with an
expiration date of May 26, 2026.

The new patent concerns compositions of humanized anti-HLA-DR antibodies of
use for disease therapy. The allowed claims protect IMMU-114, which is being
investigated as a monotherapy in a newly-opened Phase I dose-escalation trial
in patients with relapsed or refractory non-Hodgkin lymphoma or chronic
lymphocytic leukemia.

HLA-DR is a receptor located on the cell surface whose role is to present
foreign objects to the immune system for the purpose of eliciting an immune
response. Increased presence of HLA-DR in hematologic cancers has made it a
prime target for antibody therapy.

Although other anti-HLA-DR antibodies have been developed, IMMU-114 is
distinguished by having a different immunoglobulin class, IgG4, which does not
function by the usual effector-cell activities of antibodies, such as
complement-dependent cytotoxicity (CDC) and antibody-dependent cellular
cytotoxicity (ADCC). As a result, IMMU-114 does not rely on an intact immune
system in the patient to kill tumor cells. Furthermore, because ADCC and CDC
are believed to play a major role in causing the side effects of antibody
therapy, IMMU-114 is expected to be less toxic to patients.

IMMU-114 has exhibited in vitro and in vivo cytotoxicity on a number of human
lymphoma cell lines, as well as a panel of leukemia cell lines. Moreover, in
one animal model of human NHL, treatment with the anti-HLA-DR antibody was
more effective than rituximab in yielding 100% long-term survival.

"IMMU-114 is another innovative product candidate our research scientists have
developed," remarked Cynthia L. Sullivan, President and Chief Executive
Officer. "Our recent work on its mechanism of action demonstrated that the
anti-HLA-DR antibody exerts its exceptional anti-tumor activity through
disruption of 2 cellular signaling pathways, ERK and JNK, that are critical
for cell growth. This mechanism of action clearly differentiates IMMU-114 from
other antibody-based therapies of B-cell cancers, which may allow for
combination therapies with other antibodies to be developed. We are pleased to
receive this patent protection," Ms. Sullivan concluded.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune disorders and other serious diseases. Immunomedics' advanced
proprietary technologies allow the Company to create humanized antibodies that
can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these
technologies, Immunomedics has built a pipeline of nine clinical-stage product
candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB),
who has worldwide rights in non-cancer indications to Immunomedics' Phase III
product candidate, epratuzumab. UCB expects Phase III data in systemic lupus
erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring
epratuzumab in oncology in collaboration with outside cancer study groups.
Immunomedics' most advanced wholly owned candidate is ^90Y-clivatuzumab
tetraxetan, which is in an ongoing Phase III registration trial in patients
with pancreatic cancer. Immunomedics' portfolio of wholly owned product
candidates also includes antibody-drug conjugates (ADCs) that are designed to
deliver a specific payload of a chemotherapeutic directly to the tumor while
reducing overall toxicity effects that typically occur when these
chemotherapeutic agents are dosed alone.Immunomedics' most advanced ADCs are
IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid
tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics
also has a number of other product candidates that target solid tumors and
hematologic malignancies, as well as other diseases, in various stages of
clinical and pre-clinical development. These include bispecific antibodies
which have application as T-cell redirecting immunotherapies targeting cancers
and infectious diseases as well as next-generation therapies in cancer and
autoimmune disease. Immunomedics creates these bispecific antibodies using its
patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company
believes that its portfolio of intellectual property, which includes
approximately 248 active patents in the United States and more than 400
foreign patents, protects its product candidates and
technologies.Immunomedics' strength in intellectual property has resulted in
the top-4 ranking in the January 2014 Patent Board scorecard in the
Biotechnology industry. For additional information on the Company, please
visit its website at The information on its website does
not, however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials (including the funding therefor, outcomes, timing or associated costs),
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, potential collaborations,
and capital raising activities, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are not limited
to, new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on UCB for the further development of
epratuzumab for non-cancer indications, risks associated with the outcome of
pending litigation, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company's filings with the Securities
and Exchange Commission.The Company is not under any obligation, and the
Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.